Patient Square Capital LP
13F Reported Value
ⓘ$645.5M
Holdings
23
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Patient Square Capital LP disclosed 23 positions worth $645.5M in its Form 13F-HR for Q2 2026, led by $ROIV (Roivant Sciences Ltd.) at 44.0% of the equity portfolio, followed by $RVMD and $MIRM. During the quarter the fund opened 6 new positions and exited 12 — including a new stake in $RVMD and a full exit from $INSM. The portfolio is most concentrated in Healthcare (97.7% of disclosed assets). All figures are sourced directly from Patient Square Capital LP’s Form 13F-HR filing with the SEC under CIK 1819257.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$283.9M8,020,928 sh - —
Quality
$51.7M276,000 sh - 35.0#2,321
Quality
$30.5M260,500 sh - —
Quality
$27.5M206,500 sh - —
Quality
$25.7M90,020 sh - —
Quality
$23.2M671,209 sh - —
Quality
$21.3M23,000 sh - 71.3
Quality
$20.1M37,120 sh - —
Quality
$16.9M110,000 sh - —
Quality
$16.4M425,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Roivant Sciences Ltd.$ROIV | — | $283.9M | 8,020,928 |
 Revolution Medicines, Inc.$RVMD | — | $51.7M | 276,000 |
 Mirum Pharmaceuticals, Inc.$MIRM | 35.0#2,321 | $30.5M | 260,500 |
 Abivax S.A.$ABVX | — | $27.5M | 206,500 |
 BeOne Medicines Ltd.$ONC | — | $25.7M | 90,020 |
 Pharvaris N.V.$PHVS | — | $23.2M | 671,209 |
 ARGENX SE$ARGX | — | $21.3M | 23,000 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $20.1M | 37,120 |
 BELITE BIO, INC$BLTE | — | $16.9M | 110,000 |
 Cogent Biosciences, Inc.$COGT | — | $16.4M | 425,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Patient Square Capital LP's 23 positions.
Showing top 10 of 23 holdings.
Sector Allocation
Healthcare
$630.9M
Technology
$10.3M
Other
$4.4M
Full Holdings — Patient Square Capital LP (Q2 2026)
All 23 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ROIV | Roivant Sciences Ltd. | $283.9M | 44.0% | -2% | — |
| 2 | $RVMD | Revolution Medicines, Inc. | $51.7M | 8.0% | NEW | — |
| 3 | $MIRM | Mirum Pharmaceuticals, Inc. | $30.5M | 4.7% | +13% | 35 |
| 4 | $ABVX | Abivax S.A. | $27.5M | 4.3% | +70% | — |
| 5 | $ONC | BeOne Medicines Ltd. | $25.7M | 4.0% | +12% | — |
| 6 | $PHVS | Pharvaris N.V. | $23.2M | 3.6% | +36% | — |
| 7 | $ARGX | ARGENX SE | $21.3M | 3.3% | -37% | — |
| 8 | $UTHR | UNITED THERAPEUTICS Corp | $20.1M | 3.1% | NEW | 71.3 |
| 9 | $BLTE | BELITE BIO, INC | $16.9M | 2.6% | -6% | — |
| 10 | $COGT | Cogent Biosciences, Inc. | $16.4M | 2.5% | -29% | — |
| 11 |  $DBVT | DBV Technologies S.A. | $14.9M | 2.3% | +31% | — |
| 12 |  $XENE | Xenon Pharmaceuticals Inc. | $13.3M | 2.1% | -3% | 24 |
| 13 |  $BNTX | BioNTech SE | $12.5M | 1.9% | NEW | — |
| 14 |  $RCUS | Arcus Biosciences, Inc. | $11.0M | 1.7% | +82% | 8.5 |
| 15 |  $ELVN | Enliven Therapeutics, Inc. | $10.8M | 1.7% | +6% | — |
| 16 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $10.5M | 1.6% | +15% | 22.6 |
| 17 |  $ALLO | Allogene Therapeutics, Inc. | $10.5M | 1.6% | +46% | 33.9 |
| 18 |  $EYPT | EyePoint, Inc. | $10.3M | 1.6% | -9% | 3.5 |
| 19 |  $ARQT | Arcutis Biotherapeutics, Inc. | $9.7M | 1.5% | -8% | 62.9 |
| 20 |  $CCCC | C4 Therapeutics, Inc. | $7.5M | 1.2% | NEW | 18.2 |
| 21 |  $IVA | Inventiva S.A. | $7.4M | 1.1% | NEW | — |
| 22 |  $KYMR | Kymera Therapeutics, Inc. | $5.4M | 0.8% | -53% | 28.4 |
| 23 | — | FAETH THERAPEUTICS INC - COM NEW | $4.4M | 0.7% | NEW | — |
New Positions (6)
Exited Positions (12)
$INSM INSMED Inc
$LEGN Legend Biotech Corp
$NKTR NEKTAR THERAPEUTICS
$CELC Celcuity Inc.
$MRK Merck & Co., Inc.
$CATX Perspective Therapeutics, Inc.
$DFTX Definium Therapeutics, Inc.
$HROW HARROW, INC.
$TARA Protara Therapeutics, Inc.
$CTMX CytomX Therapeutics, Inc.
$ASMB ASSEMBLY BIOSCIENCES, INC.
$SYRE Spyre Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Patient Square Capital LP including:
Track Patient Square Capital LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Patient Square Capital LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Patient Square Capital LP
13F Pro is an AI hedge fund tracker and stock research platform. For Patient Square Capital LP (SEC CIK: 1819257), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Patient Square Capital LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.